Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes
Xconomy
JUNE 3, 2016
But billions of dollars in acquisitions will be left by the side of the road. Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin).
62 
Let's personalize your content